Renal cell carcinoma stage IV

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (CTLA-4) 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Kinase inhibitor 1 substance
Phase III: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase III

1 trial
  • Bristol Myers Squibb International Corporation Commercial
    IPILIMUMAB; NIVOLUMAB; SUNITINIB
    2023-504761-23-00 13 countries 2014 n=578
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bristol Myers Squibb International Corporation Commercial 1 Phase III 0
← All indication landscapes